Cookie Recall as 'Serious' Health Warning Issued
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A California-based company is recalling various cookie products due to the possible undeclared presence of allergens that could cause "serious" health issues, according to the U.S. Food and Drug Administration (FDA).
Jalux Americas, Inc., doing business as J.sweets, issued a voluntary recall on July 14 for multiple units of its L'espoir cookies because of undeclared milk, and its Drycapot cookies because of undeclared tree nuts (almond and macadamia nuts).
Newsweek contacted Jalux Americas Inc. for comment by email outside regular working hours.
Jalux Americas Inc. issued a voluntary recall on July 14 for multiple units of its cookie products due to the undeclared presence of allergens.
Jalux Americas Inc. issued a voluntary recall on July 14 for multiple units of its cookie products due to the undeclared presence of allergens.
Christoph Schmidt/picture-alliance/dpa/AP
Why It Matters
Milk and tree nuts are two of the nine major food allergens as defined in law. The others are eggs, fish, crustacean shellfish, peanuts, wheat, soybeans and sesame.
The FDA warned that people with an allergy or severe sensitivity to milk or tree nuts "run the risk of serious or life-threatening allergic reaction if they consume these products."
Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems.
What To Know
The products impacted by the recall are:
L'espoir cookies - 32 units - code: L4FN - best before date: 09/26/2025 - bar code number: 4 942737 200147
Drycapot cookies - 28 units - code: D4FN - best before date: 09/26/2025 - bar code number: 4 942737 210191
The recalled products were distributed in California, Illinois and Washington. The cookies were sold exclusively at J.sweets stores in Torrance, San Jose, Arlington Heights and Lynnwood.
The L'espoir cookies were sold between May 26 and June 30, and the Drycapot cookies were for sale between May 31 and June 31. Neither were available for purchase online.
No illnesses had been reported in connection with the consumption of the affected products as of July 17, according to the FDA.
The recall was issued after an inventory audit revealed that the products' packaging did not reveal the presence of the two allergens.
What People Are Saying
The FDA, on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food."
Dr. Sebastian Lighvani, director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
The recall is ongoing, according to the FDA.
Consumers who purchased the recalled products are advised to return them to their place of purchase for a full refund.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
Family Health Services of Darke County and AndHealth Celebrate Ribbon Cutting and Launch of Retail + Specialty Pharmacy at Expanded Greenville Location
GREENVILLE, Ohio--(BUSINESS WIRE)--Family Health Services of Darke County and AndHealth will celebrate the opening of Family Health Services' retail and specialty pharmacy on Thursday, August 7 th at 4:00 PM. The ribbon cutting will take place at Family Health Services' newly expanded Greenville facility, located at 5735 Meeker Road, and will be followed by an open house from 5:00 – 8:00 PM featuring light refreshments, family-friendly activities, and tours of the renovated space. "With this expansion, we're not just adding services, we're closing care gaps and removing barriers to health for our neighbors.' This milestone marks a major step forward in Family Health Services' mission of Building Healthy Lives Together. This expansion adds 44,000 square feet of clinical space, modernizes the patient experience, and introduces expanded pharmacy services, including the launch of Darke County's only specialty pharmacy. These enhancements will significantly improve access for patients managing chronic and complex conditions, particularly those impacted by long-standing pharmacy shortages in rural Ohio. Family Health Services' specialty pharmacy services are powered by a partnership with AndHealth, a Columbus-based healthcare company that helps CHCs radically improve access and outcomes to specialty care. Ohioans can now fill their prescriptions directly through Family Health Services' pharmacy, where affordable medications are available to all patients under Family Health Service's sliding fee scale. 'There is an immense value in having specialty care and pharmacy services directly within our community,' said Jared Polick, Executive Director and CEO of Family Health Services. 'Residents of Darke County will now be able to receive care close to home and have the personal support of local clinical pharmacists and specialists. With this expansion, we're not just adding services, we're closing care gaps and removing barriers to health for our neighbors.' The updated Greenville facility now offers integrated medical, behavioral health, dental, rheumatology, dermatology, neurology, and pharmacy services under one roof – creating a true whole-person care environment that prioritizes convenience, coordination, and affordability. Addressing Ohio's Pharmacy Deserts and Improving Medication Access According to new data 1 released by the Ohio Board of Pharmacy, pharmacy closures have accelerated, and the state has lost hundreds of pharmacies over the past several years, leaving Ohioans with less than 2,000 retail pharmacies. Nearly 2 million Ohioans live in 'pharmacy deserts', or areas that lack convenient access to a pharmacy. 2 These access deserts disproportionately impact individuals in socially vulnerable communities, who face additional barriers to access and care, making the role of pharmacies located at CHCs even more central to improving community health in Ohio. AndHealth partners with Community Health Centers (CHCs) like Family Health Services to expand access to care by addressing pharmacy and care deserts. 'Ensuring our patients have access to affordable medications can only be accomplished when we reverse the trend of pharmacy consolidation and closure,' said Brenda Reitz, Family Health Services' Pharmacy Director. 'This pharmacy expansion allows us to support the community in new ways and ensures our neighbors needs can be met right here in Darke County.' Family Health Services' ribbon cutting will take place at its 5935 Meeker Rd location in Greenville at 4:00 P.M. on August 7 th with an open house to follow from 5:00 – 8:00 PM. The event is open to all, and guests are encouraged to RSVP by contacting Kalie Riffle at kriffle@ About Family Health Services Family Health Services is a Federally Qualified Health Center (FQHC) dedicated to building healthier lives through integrated, affordable care. With locations across Darke County, FHS provides comprehensive services – including medical, dental, behavioral health, specialty care, and pharmacy – to patients of all ages, regardless of insurance status or ability to pay. To learn more, visit About AndHealth AndHealth helps Community Health Centers (CHCs) radically improve access and outcomes for patients in specialty care and specialty pharmacy, while becoming an even larger and more clinically integrated part of our healthcare system. This Whole-Person Community Care Model provides everything CHCs need to deliver in-house specialty care and specialty pharmacy, built for the unique needs of our medically underserved populations. The model provides CHCs with more patients, more clinical capabilities, alignment with health systems, and sustainable reimbursement and funding that restores the integrity of the patient's medical home and their critical reimbursement model—both having shifted away from CHCs through external specialty referrals and contract pharmacies. In restoring this integrity, CHCs can tear down barriers to care and stretch scarce federal resources to reach more patients with comprehensive services that weren't possible before and that are desperately needed by patients. Headquartered in Columbus, Ohio, AndHealth is led by former CoverMyMeds co-founder and CEO Matt Scantland and the team that built Ohio's first healthcare technology unicorn, who have dedicated their lives to transformative innovation that improves access for patients. AndHealth is supported by key investors including the American Medical Association's innovation subsidiary, Francisco Partners, and the state of Ohio's economic development organization. To learn more, visit
Epoch Times
30 minutes ago
- Epoch Times
Freeze-Dried Fruit Sold at Sam's Club Stores Recalled Nationwide
Georgia-based Dohler Dry Ingredient Solutions, LLC, is recalling its dried fruit products due to contamination with Listeria monocytogenes bacteria, the company said in a July 31 announcement published by the Food and Drug Administration (FDA). The product—Member's Mark Freeze Dried Fruit Variety Pack—was sold in 15-count boxes. The items were distributed between July 1 and July 25 via Sam's Club retail stores across 43 states.
Business Upturn
33 minutes ago
- Business Upturn
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
By GlobeNewswire Published on August 4, 2025, 23:31 IST PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to FDA and to be conducted by Immuthera has been received favorably, may include Polish patients in the U.S. Statistical analysis, and could be treated as pivotal. The project has received an $11.3 million non-dilutive grant from the Polish Medical Research Agency. PolTREG is developing Multi-edited, Allogeneic CAR-Tregulatory cell therapies which can be used to treat patients diagnosed with T1D (Stage 3), which, in combination with PTG-007 in Stage 1 and Stage 2, will provide clinical solutions for patients across all Stages of T1D. 4 August 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a pioneer in cell therapies for autoimmune diseases, and its U.S. subsidiary Immuthera, announced that they have administered the first dose of PTG-007 to a patient in their Phase II clinical trial for pre-symptomatic type 1 diabetes. The trial, called 'Pre-Treg' will enroll up to 150 genetically high-risk children and adolescents (aged 3–18) who have not yet developed clinical symptoms of the disease. If successful, PolTREG aims to develop and register the world's first therapy to prevent the onset of type 1 diabetes symptoms. The company has proposed a parallel study to Pre-Treg to the U.S. Food and Drug Administration (FDA) in a recent Pre-IND meeting. The FDA's response was that the U.S. Trial could potentially be registrational. Further, patients enrolled in Poland at Stage 1 of the disease may, upon completion of enrollment, be included in the U.S. statistical analysis of the study. 'Long-term data from our clinical program of PTG-007 in symptomatic type 1 diabetes confirm both the safety and efficacy of the therapy. Modern medicine is increasingly focusing on interventions applied earlier or even before the first clinical symptoms appear. Our therapy fits perfectly into this paradigm. By administering it at the earliest stage of disease development, we anticipate highly promising outcomes—possibly even halting disease progression before clinical symptoms emerge. If the trial confirms the therapy's efficacy, we have the opportunity to develop and register the world's first drug to prevent the clinical onset of type 1 diabetes. We believe this therapy holds significant market and partnership potential' – said Prof. Piotr Trzonkowski, CEO and Co-Founder of PolTREG S.A. The Phase II study will include 150 participants in a randomized, placebo-controlled design. Recruitment is ongoing at three academic centers in Poland, with six additional clinical hospitals set to begin enrollment shortly. PolTREG has been awarded a non-dilutive grant of PLN 31.7 million (approx. $11.3 million) from the Polish Medical Research Agency to support the execution of this Phase II trial. PreTreg is one of PolTREG's flagship programs. In type 1 diabetes, the autoimmune destruction of insulin-producing pancreatic islets underscores the importance of early intervention. In the pre-symptomatic phase, a sufficient number of islets remain to maintain normal glucose regulation, and the autoimmune process is still limited and more readily controllable. Preventive therapy at this stage could halt the autoimmune attack, leaving patients genetically predisposed but clinically healthy for life. Upon successful completion of this trial and confirmation of safety and efficacy, PolTREG could establish the first approved drug to prevent symptomatic type 1 diabetes. Type 1 diabetes progresses through three stages. Stages 1 and 2 is considered presymptomatic and occurs in young children, typically 3 years old or older. Because these patients are not yet sick, safety is the highest priority. PTG-007's 12 year safety data makes it an ideal treatment for this age group and this stage of disease. Diagnosis of Type 1 Diabetes occurs in Stage 3 when symptoms occur which can lead to potentially life threatening complications such as diabetic ketoacidocis, heart and blood vessel disease, nerve damage, eye damage, kidney disease, and foot damage. These patients are typically older and require supplemental insulin. Due to the complications in Stage 3, more aggressive treatments are warranted. PolTREG and Immuthera are developing Tregulatory cell therapies that have clinically derived edits to improve function, modifications to make them 'off-the-shelf' (allogeneic), and a Chimeric Antigen Receptor to improve targeting of the disease causing cells that drive the autoimmune response. Taken together, PolTREG and Immuthera have a pipeline of Tregulatory cell therapies that will cover the full spectrum of presymptomatic and symptomatic Type 1 Diabetes. PolTREG is also expanding its U.S. presence. In mid-June, the company established its wholly owned U.S. subsidiary, Immuthera, registered as a Delaware C Corporation. In recent weeks, prominent experts in diabetes and neuroimmunology—Prof. Jay Skyler, Prof. Desmond Schatz, and Prof. Lawrence Steinman—joined the company's Scientific Advisory Board. In late July, PolTREG received the formal outcome of its pre-IND meeting with the FDA and is now preparing its IND submission. The company has partnered with Noble Capital Markets, Inc. and Kinexum Services LLC to support its U.S. regulatory strategy, and is collaborating with Swiss-based Antion Biosciences to develop next-generation allogeneic Treg therapies. About PolTREG: PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera: Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities and asset pipeline along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For further information please contact: PolTREG Piotr TrzonkowskiChief Executive Officer [email protected] +48 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
